CD22

CD22 (Siglec 2) 是一种分子量为 135-kDa 的 B 细胞限制性抗原，是 B 细胞受体 (BCR) 的抑制性辅助受体。CD22 的胞外结构包含七个免疫球蛋白结构域，并负责结合 α2,6Sia 配体。当 CD22 与这些 cis 配体 (在 B 细胞表面) 相互作用时可调节 CD22 与 BCR 的结合，从而调节 CD22 的抑制功能；当 CD22 与 trans 配体 (在其他细胞表面) 相互作用时可以调节 B 细胞迁移和 BCR 信号阈值。
CD22 还可以将酪氨酸磷酸酶 (SHP-1) 募集到免疫受体酪氨酸抑制基序 (ITIM) 并抑制正常 B 细胞上 BCR 诱导的 Ca²⁺ 信号传导。CD22 对于维持 B 细胞抑制功能和体液免疫稳态的基线水平至关重要。CD22 是失调 B 细胞 (导致自身免疫性疾病和血癌) 的靶标分子^[1]^[2]。

CD22 (Siglec 2) is a 135-kDa B-cell restricted antigen, and is an inhibitory coreceptor of the B-cell receptor (BCR). The extracellular portion of CD22 comprises seven immunoglobulin domains, and is responsible for binding α2,6Sia ligands. Interaction with these ligands in cis (on the B-cell surface) regulates the association of CD22 with the BCR and thereby modulates the inhibitory function of CD22. Interaction of CD22 to ligands in trans (on the surface of other cells) can regulate both B-cell migration as well as the BCR signaling threshold.
CD22 can also recruit the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits BCR-induced Ca²⁺ signaling on normal B cells. CD22 is critical in maintaining a baseline level of B-cell inhibition and homeostasis in humoral immunity. CD22 is a target molecule in dysregulated B cells that cause autoimmune diseases and blood cancers^[1]^[2].

CD22 相关产品（1）

货号	产品名	Cas	产品描述
PL06072	Inotuzumab	1660159-36-3	Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) 是人源化的 IgG4，κ 抗体靶向人 CD22。Inotuzumab 与毒素奥加米星 (ozogamicin) 相连接可作为抗体-药物偶联物 (ADC)。Inotuzumab 可于急性淋巴细胞白血病和非霍奇金淋巴瘤的研究。